Loading... Please wait...

Our Newsletter


  • LY-2228820 (200x200px)
  • LY-2228820 (600x600px)
Catalog #:

Product Description

LY2228820 is a potent and selective ATP-competitive inhibitor of the α- and β-isoforms of p38 mitogen-activated protein kinases (MAPKs). It inhibits p38α and p38β with IC50 values of 5.3 nM and 3.2 nM, respectively. [1] In cell-based assays, LY2228820 selectively inhibited the level of phospho-MAPKAP-K2 (pMK2) in anisomycin-induced RAW264.7 cells, with IC50 of 35.3 nM. LY2228820 also inhibits lipopolysaccharide (LPS)/IFN-γ-induced TNFα formation in murine peritoneal macrophages, with IC50 of 6.3 nM. [1] Furthermore, LY2228820 inhibits angiogenic endothelial cord formation in multiple in vitro and in vivo assay models. [2]
LY2228820 is currently being evaluated in Phase I/II clinical trials in patients with newly diagnosed glioblastoma [3] and platinum-sensitive ovarian cancer [4]."

Technical information:

Chemical Formula:   C24H29FN6.2CH4O3S
CAS #:   862507-23-1
Molecular Weight:   612.74
Purity:   > 98%
Appearance:   Off-white
Chemical Name:   5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate
Solubility:   Up to 100 mM in DMSO
Synonyms:   LY-2228820, LY2228820, LY2228820 dimesylate,

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.


1. Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014; 13(2):364-74 Pubmed ID: 24356814
2. Tate CM, et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J Biol Chem. 2013; 288(9):6743-53 Pubmed ID: 23335506
3. Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma (GLYRad). clinicaltrials.gov/NCT02364206 
4. A Study of LY2228820 for Recurrent Ovarian Cancer.  clinicaltrials.gov/NCT01663857

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the LY-2228820 to your wish list.

You Recently Viewed...